Medtronic PLC $MDT Position Reduced by Madison Asset Management LLC

Madison Asset Management LLC trimmed its position in Medtronic PLC (NYSE:MDT) by 35.4% in the third quarter, HoldingsChannel.com reports. The firm owned 169,689 shares of the medical technology company’s stock after selling 93,111 shares during the quarter. Madison Asset Management LLC’s holdings in Medtronic were worth $16,161,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of MDT. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the third quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic during the third quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC bought a new stake in Medtronic during the third quarter worth approximately $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Medtronic Stock Down 0.3%

Shares of Medtronic stock opened at $101.37 on Wednesday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market cap of $129.96 billion, a P/E ratio of 27.32, a P/E/G ratio of 2.68 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $99.36 and a 200 day moving average price of $96.28.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. CICC Research initiated coverage on Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. Royal Bank Of Canada boosted their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. UBS Group reiterated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Wells Fargo & Company assumed coverage on Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. Finally, Truist Financial reduced their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $111.21.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).